Immunovia AB announced that it enters into a strategic partnership with Proteomedix to leverage its substantial joint development experience in diagnostic technologies for the detection of cancer. This will enable increased R&D productivity for Immunovia as the Company continues to strengthen its commercial development in the US. The partnership between Immunovia and Proteomedix leverages the companies' complementary R&D capabilities and advances their R&D efforts.

With this partnership, Immunovia will gain a more flexible R&D organization, increase its R&D productivity, and will focus internal resources on the commercial build up, thus further accelerating the roll-out of IMMray(TM) PanCan-d.? The partnership capitalizes on the combined expertise of two leading innovators in proteomics-based diagnostics, who have both launched innovative oncology tests, Immunovia with IMMray(TM) PanCan-d in the U.S. and Proteomedix with Proclarix® in Europe. Proteomedix, a Swiss based Company, was founded 2010 as a spin-off company of ETH Zurich to bring together the expertise of a multi-disciplinary group of scientists and clinicians in proteomic-based diagnostics.

The Company is focused on research and development that relies on a network of clinicians, IVD experts, laboratories, and marketers. Proteomedix has developed a blood-based prostate cancer test using proteomics technology that measures cancer-associated proteins, using highly reproducible immunoassays.